Samsung Biologics has unveiled a series of proprietary development platforms as part of continued efforts to ensure high-quality development and provide client-tailored services.

S-AfuCHO, introduced at BioProcess International 2024, is a cell line platform that can generate afucosylated antibodies that exhibit enhanced antibody-dependent cellular cytotoxity (ADCC) activity for increased therapeutic efficacy.

The platform removes the core fucose from Fc N-glycans through knockout of the host (FUT8) gene to achieve higher ADCC activity while retaining desired titers, stability, and product quality.

S-OptiCharge is an upstream process platform that can modulate a molecule's charge variant distribution. Modifications can occur at any step of the manufacturing process, impacting product safety and efficacy.

The platform minimizes charged variants within samples while maximizing the main molecular form to ensure safe therapeutic effects. By optimizing media, additives, and process parameters and using a thorough screening procedure, S-OptiCharge ensures high product quality through tight control over critical quality attributes to achieve optimal charge variant distribution.

"Our new platforms are expected to provide clients with high-performing solutions for their molecules to reduce risks and support successful development. We will continue to develop innovative solutions to proactively address the evolving needs of our clients and meet increased demand for complex and high-concentration biopharmaceuticals," said Jahoon Kang, Vice President of CDO at Samsung Biologics.